A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Ramipril (Vostally)

Angiotensin Converting Enzyme Inhibitor class · 8 generic manufacturers · 31 ANDAs filed at FDA.

First FDA approval2008-06-10
Generic availableYes · 8 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$27.4M in CY2024 Part D spend2.3M claims · 714K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.053/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.054
Across all dosage forms in distribution.
Highest NADAC
$0.058
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Ramipril used for?

Ramipril is a Angiotensin Converting Enzyme Inhibitor medication tracked in Medicare Part D.

Is there a generic for Ramipril?

Yes. 31 ANDAs filed at FDA, 8 generic manufacturers currently shipping.

How much does my plan pay for Ramipril?

Across 329 Part D plans, Ramipril averages $0.054/unit (NADAC). Lowest available: $0.053/unit. Highest in distribution: $0.058/unit.

Is Ramipril on the FDA shortage list?

No. Ramipril is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Angiotensin Converting Enzyme Inhibitor4 alternatives in D1
01
Captopril
Angiotensin Converting Enzyme Inhibitor
$0.138Lowest NADAC
7Generic mfrs
$7.1MCY24 Part D spend
Compare →
02
Trandolapril
Angiotensin Converting Enzyme Inhibitor
$0.190Lowest NADAC
3Generic mfrs
$2.0MCY24 Part D spend
Compare →
03
Trandolapril Tablets
Brand: Trandolapril
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
04
Trandolapril and Verapamil
Angiotensin Converting Enzyme Inhibitor
Lowest NADAC
1Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.